PHARMACOLOGICAL PROPERTIES OF DRUGS USED IN BRONCHIAL ASTHMA

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus species (usually A. fumigatus) that occurs primarily in patients with asthma and, less commonly, cystic fibrosis. Immune reactions to Aspergillus antigens lead to airway obstruction and, if untreated, to bronchiectasis and pulmonary fibrosis. The signs and symptoms are consistent with those of bronchial asthma, with productive cough, sometimes fever, and anorexia. To confirm the diagnosis, skin testing for Aspergillus is performed and levels of IgE, circulating precipitins, and antibodies to A. fumigatus are determined. In refractory cases, treatment is with corticosteroids and itraconazole.